Follow The Rules Of Compounding
Compounding glucagon-like peptide-1 (GLP-1) receptor agonists is quickly becoming a useful strategy for providing custom weight management and type 2 diabetes treatment. Yet, making new forms of GLP-1 is not straightforward and available to all pharmacies. Strict regulations are in place, creating complex challenges that require careful navigation to ensure compliance. Food and drug administration (FDA) regulations and guidance continue to change as demand for these medications increases. For compounding therapies to thrive, understanding the regulatory landscape is essential to ongoing trust and success. Along with understanding, implementing appropriate strategies allows pharmacies to operate confidently and within legal limits. This ensures patients can consistently get access to medication like GLP-1s and other compounded formulations.
FDA distinctions for GLP-1 compounding
The FDA has a list of requirements specific to compounding individual and larger batches of medication. Section 503A applies to traditional pharmacies that can compound GLP-1 medications only for individual patients with valid prescriptions. This is on a case-by-case basis, so facilities cannot produce or store large batches for general use. Compounding under section 503B, on the other hand, refers to those who are authorized to produce larger batches of compounded GLP-1 medications. These solutions are ideal for healthcare facilities, physicians, and pharmacies for resale. These compound pharmacies must follow all rules, including current good manufacturing practice (cGMP) requirements. Whatever the purpose, these 3 tips can help pharmacies navigate regulations.
1. Set your standards high
All compounding pharmacies must strive to have clear policies, which in turn help to maintain regulatory standards. These policies ensure compounding remains within all expected boundaries. A typical example involves verifying that valid prescriptions exist before beginning any GLP-1 solution. Pharmacies that produce larger batches should have internal standards for cGMP compliance. This should include regular review of FDA rules, which can evolve during shortages. These policies should extend to sourcing the best active pharmaceutical ingredients (APIs) possible. GLP-1 ingredients must come from FDA-registered suppliers who provide comprehensive certificates of analysis (COA) demonstrating compliance. Add in procedures for verifying identity, purity, potency, and specific impurities. These policies minimize errors, reduce risk, and enable pharmacies to provide the best possible medication.
2. Have robust API qualification and documentation
Producing high-quality GLP-1 requires a strong supplier system. Implement steps and qualification programs that confirm API manufacturers are compliant with a track record of consistency. Documentation is key, ensuring regulations and requirements are met from all sides. Capture each step from quality-related decisions to confirmation of each GLP-1 batch. Regular review and updating of supplier qualifications ensures continued compliance with evolving FDA expectations. Even for one-off formulations, prescription records must include detailed patient and physician information, as well as the reasons for compounding. Documentation also becomes useful if there is an adverse drug reaction or safety concerns. Compounding pharmacies that effectively evaluate these issues can respond faster to emergencies or changing protocols.
3. Exceed the bare minimum
Beyond basic regulatory requirements, successful GLP-1 compounding programs have systems that support constant improvement and demonstrate a commitment to patient safety. These systems should include detailed standard operating procedures (SOPs) and regular internal audits. Proactive communication with regulatory agencies when questions arise is another helpful quality. When concerns arise, systems provide clear evidence of appropriate practices and regulatory compliance. Additional systems help pharmacies stay current with an ever-changing landscape. As the FDA manages shortages and evaluates data from compounding products, requirements should change. Implementing individuals and systems that periodically evaluate FDA regulations helps teams stay proactive.
A culture of compliance
Successful navigation of GLP-1 regulations begins by making FDA regulations a part of the process. Create documentation, policies, and systems that reflect a commitment to learning and abiding by these rules. Train staff on the importance of documentation, quality control, and patient safety. Ensure all major stakeholders understand FDA regulations. This helps identify potential issues beforehand, thereby preserving patient safety. Long-term success in GLP-1 compounding can be beneficial for pharmacies. Not only can pharmacies build more trust, but the pharmacy’s reputation for quality and reliability creates competitive advantages and boosts long-term success.
